In making its decision, the court said that Mirinia has “raised only serious questions” on the merits of its trademark infringement claim, and not shown that it would suffer “irreparable harm” if Marina is allowed to continue using its newly acquired moniker.
Adding to the difficulty in raising funds, there has also been an increase in the number of companies operating in the miRNA space in recent years, many of which are on the lookout for their share of available investment dollars.
In court filings obtained by Gene Silencing News, Marina argued that the two companies' names are sufficiently different that they would not be confused by the savvy and educated players in the RNAi and miRNA spaces.
At the Rodman & Renshaw Healthcare Conference in New York this Week, a company official noted that in work conducted with Mirna Therapeutics, Marina found a 100-fold increase in microRNA in three different tissues, along with downregulation of the intended gene targets.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.